As of June this year, based on Incyte's latest financial report, the company's current EPS (TTM) is $7.29. In 2025, INCY reported a per-share earnings of $6.59, which represents an increase compared to the EPS of $0.16 recorded in 2024. Incyte's EPS for the quarterly period ending on Mar 31, 2026 was $1.52.
The yearly EPS in 2025 was $6.59, an increase of 4,018.8% compared to $0.16 recorded in 2024. For the quarter ending Mar 31, 2026, the EPS was $1.52, reflecting a 85.4% increase compared to the same quarter a year earlier. The trailing twelve months (TTM) EPS as of March 2026 is $7.29. In 2024, the annual EPS was $0.16, showing a decrease of 94% compared to 2023.
Incyte has recorded a growth in earnings per share of 85.4% over the past 12 months (YoY, quarterly). Looking at a longer timeframe, the company recorded an average EPS annual growth rate of 62.7% per year for the last 3 years. A ten-year view shows that INCY has seen an average earnings per share growth of 66.6% per year.
| Stock name | Price to Earnings | EPS grwoth 1Y | EPS grwoth 3Y | EPS grwoth 5Y |
|---|---|---|---|---|
| INCY Incyte Corp | 13.89 | 4,018.8% | 62.7% | N/A |
| PFE Pfizer Inc | 19.61 | -3.5% | -37.4% | -3.7% |
| NVS Novartis AG | 21.14 | 21.8% | 31.2% | 15.2% |
| AMGN Amgen Inc | 23.87 | 88.1% | 5.6% | 2.9% |
| LGND Ligand Pharmaceuticals Inc | 29.83 | 3,027.3% | N/A | N/A |
| LLY ELI LILLY & Co | 39.88 | 95.6% | 49.2% | 27.5% |
| ARDX Ardelyx Inc | N/A | -52.9% | N/A | N/A |
| GERN Geron Corp | N/A | 51.9% | N/A | N/A |
All data is based on quarterly TTM periods, unless otherwise specified.